Boston, United States
TearClear is an emerging ophthalmic pharmaceutical company founded in 2015 and headquartered in the United States. The company is focused on disrupting the delivery of current topical medications to the ocular surface, particularly in the treatment of glaucoma. Their lead product candidates aim to enhance patient safety and compliance by capturing preservatives before they reach the ocular surface.
With a slogan of "Ensuring efficacy without compromising the safety of the ocular surface," TearClear is positioned as a pioneer in this first-in-class platform of drugs. The company's innovations have attracted significant attention from investors, with their $11.76M Venture Round investment on 11 July 2023 underlining the confidence in their potential.
Operating within the Medical Devices and Pharmaceutical industries, TearClear's unique approach to drug delivery is not only innovative but also addresses a critical need in ophthalmic care. As the company continues to progress, it has the potential to make a significant impact across multiple programs in development and future indications.
